Health Care & Life Sciences » Biotechnology | Akari Therapeutics PLC

Akari Therapeutics PLC

Akari Therapeutics PLC ADR
Stock Exchange NASDAQ Stock Market
Market Cap
$32.19 M
Shares Outstanding
15.86 M
Public Float
14.46 M


75/76 Wimpole Street
London London & South East W1G 9RT
United Kingdom
Employees -
Updated 07/08/2019
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Coversin, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.


View All

Raymond Prudo
Executive Chairman
Clive Stuart Richardson
Chief Executive & Operating Officer, Director